Trevigen是一家快速成长的美国生物技术公司，专注于细胞凋亡、DNA损伤和修复、肿瘤细胞功能与行为等方面研究的肿瘤研究产品和服务。Trevigen公司位于NIH所在地的马里兰州盖瑟斯堡举世闻名的270州际高速公路旁的高技术走廊。Trevigen品牌的产品通过网络、目录、杂志广告、邮件以及电话等方式进行全球营销。其分销商已遍及北美，欧洲和环太平洋地区。Trevigen是一家以研发见长的企业，一直得到National Institutes of Health的SBIR基金支持，其产品通过政府和大学招标，与大公司签订贴牌合同，国际代理商分销等方式行销全球。Trevegen其专注的发展理念，认真的质量把关，使它成为NIH周边众多技术企业中稳健的实力派。
2008年Trevigen建立了一个全新的部门，Trevigen Cell Assays(TCA) ，主要业务是为生物制药企业、政府和学术机构提供研究任务外包服务，可为客户设计和实施基于DNA损伤、修复与癌症细胞的行为先导化合物和遗传毒性筛选试验。
Trevigen, Inc. is a rapidly growing biotechnology company focused on the development of products and technology for cancer research, emphasizing apoptosis, DNA damage and repair, and cancer cell function and behavior. The company is located in the I-270 "High technology Corridor" in Gaithersburg, Maryland. Trevigen-brand research products are marketed via the Internet, catalog, journal advertising, direct mail, and telemarketing. Distributor appointments have been made in North America, Europe, and the Pacific Rim. Trevigen also has in place supply agreements with major government and university medical research centers. The company is the recipient of several SBIR grants from the National Institutes of Health, concerning technology development for the analysis of DNA damage.
Trevigen has been a long-standing provider of quality reagents and kits for researchers investigating programmed cell death and DNA damage and repair. The previous decade saw a phenomenal increase in the number of investigators studying apoptosis, but only recently has the link between DNA damage and apoptosis received significant attention. We are pleased to continue to support the growing numbers of investigators moving into these overlapping fields of research. A logical extension of our focus on cancer research has been the recent development of assays for cancer cell function and behavior including angiogenesis, cell invasion and tumor formation. As always, Trevigen brand products are manufactured to the highest standards of quality and backed by expert technical support.
Trevigen Cell Assays, (TCA) a division of Trevigen, Inc, was established in 2008 to conduct contract research work for the pharmaceutical, biotechnology, government and academic segments of the research